Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 2/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 6/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14482447 | 1.00 | KCNA3 (0.49) | KCNA3SLC6A4SLC6A3SLC6A2DPP4 | |
| SCHEMBL4553979 | 1.00 | KCNA3 (0.49) | KCNA3SLC6A4SLC6A3SLC6A2DPP4 | |
| SCHEMBL8172562 | 0.83 | DPP4 (0.46) | KCNA3SLC6A4SLC6A3SLC6A2DPP4 | |
| SCHEMBL14550036 | 0.83 | DPP4 (0.46) | KCNA3SLC6A4SLC6A3SLC6A2DPP4 | |
| SCHEMBL4431845 | 0.83 | DPP4 (0.46) | KCNA3SLC6A4SLC6A3SLC6A2DPP4 | |
| SCHEMBL4427211 | 0.83 | DPP4 (0.46) | KCNA3SLC6A4SLC6A3SLC6A2DPP4 | |
| SCHEMBL4880980 | 0.82 | ALDH1A1 (0.55) | KCNA3MAPT | |
| SCHEMBL4880976 | 0.82 | ALDH1A1 (0.55) | KCNA3MAPT | |
| SCHEMBL14482845 | 0.82 | KCNA3 (0.44) | KCNA3SLC6A4SLC6A3SLC6A2DPP4 | |
| SCHEMBL14482847 | 0.82 | KCNA3 (0.44) | KCNA3SLC6A4SLC6A3SLC6A2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130012485-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-01-10 | — | — | US | disclosed |
| EP-2124913-A1 | 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS | Novartis AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008077597-A1 | 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012485-A1 | ORGANIC COMPOUNDS | DPP4, DPP3, DPP7 | KCNA3 1364/4885SLC6A4 461/4885SLC6A3 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.